CLAIMS

1. A BMP1, TLL1 and/or TLL2 binding protein, which comprises a VH region that is 100% identical to SEQ ID NO: 7 and a VL region that is 100% identical to SEQ ID NO: 8.

2. The BMP1, TLL1 and/or TLL2 binding protein according to claim 1, which comprises a light chain that is 100% identical to SEQ ID NO: 9 and a heavy chain that is 100% identical to SEQ ID NO: 10.

3. A polynucleotide sequence encoding the BMP1, TLL1 and/or TLL2 binding protein according to any one of claims 1 and 2.

4. The polynucleotide sequence according to claim 3, which comprises SEQ ID NO: 13 encoding the heavy chain; and/or SEQ ID NO: 14 encoding the light chain.

5. An expression vector comprising the polynucleotide sequence as defined in claim 3 or claim 4.

6. A recombinant host cell comprising the polynucleotide sequence as defined in claim 3 or claim 4, or the expression vector as defined in claim 5.

7. A method for the production of a BMP1, TLL1 and/or TLL2 binding protein, which method comprises culturing the recombinant host cell of claim 6 under conditions suitable for expression of the polynucleotide sequence or expression vector, whereby a polypeptide comprising the BMP1, TLL1 and/or TLL2 binding protein is produced.

8. A pharmaceutical composition comprising the BMP1, TLL1 and/or TLL2 binding protein as defined in any one of claims 1 or 2, and a pharmaceutically acceptable diluent or carrier.

9. Use of a BMP1, TLL1 and/or TLL2 binding protein as defined in any one of claims 1 or 2, or a pharmaceutical composition as defined in claim 8 in the manufacture of a medicament for use in the treatment of a fibrosis related disease or disorder.

10. The use according to claim 9, wherein the fibrosis related disease or disorder occurs in a human.

11. A BMP1, TLL1 and/or TLL2 binding protein as defined in any one of claims 1 or 2 or a pharmaceutical composition as defined in claim 8 for use in therapy.

12. A BMP1, TLL1 and/or TLL2 binding protein as defined in any one of claims 1 or 2, or a pharmaceutical composition as defined in claim 8 for use in the treatment of a fibrosis related disease or disorder.

13. The use as defined in any one claims 9 or 12, wherein the fibrosis related disease or disorder is cardiac fibrosis, pulmonary or lung fibrosis, hepatic fibrosis, renal fibrosis, peritoneal fibrosis, or non-alcoholic steatohepatitis (NASH).

14. The use as defined in claim 13, wherein the cardiac fibrosis is hypertrophic cardiomyopathy; and the pulmonary or lung fibrosis is idiopathic pulmonary fibrosis.

15. Use of a BMP1, TLL1 and/or TLL2 binding protein as defined in any one of claims 1 or 2, or the pharmaceutical composition as defined in claim 8 in the manufacture of a medicament for promoting muscle growth and/or improving muscle function.

16. The use according to claim 15, wherein the muscle growth and/or muscle function is that of a human.

17. A BMP1, TLL1 and/or TLL2 binding protein as defined in any one of claims 1 or 2, or a pharmaceutical composition as defined in claim 8 for use in promoting muscle growth and/or improving muscle function.